FDA Approves Gleevec to Prevent Recurrence of Rare Gastrointestinal Cancer

Dec. 19, 2008--The U.S. FDA today approved Gleevec (imatinib mesylate) for a new indication – keeping cancer from growing in patients following surgical removal of a gastrointestinal stromal tumor or GIST.

The details can be read here.